In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria

References

• Alam A, Goyal M, Iqbal MS, Pal C, Dey S, Bindu S, Maity P, Bandyopadhyay U. 2009. Novel antimalarial drug targets: hope for new antimalarial drugs. Expert Rev Clin Pharmacol. 2:469–489.
   PubMedGoogle Scholar
• Altincicek B, Hintz M, Sanderbrand S, Wiesner J, Beck E, Jomaa H. 2000. Tools for discovery of inhibitors of the 1-deoxy-D-xylulose 5-phosphate (DXP) synthase and DXP reductoisomerase: an approach with enzymes from the pathogenic bacterium Pseudomonas aeruginosa. FEMS Microbiol Lett. 190:329–333.
   PubMed Web of Science ®Google Scholar
• Andrews PR, Lloyd EJ. 1982. Molecular conformation and biological activity of central nervous system active drugs. Med Res Rev. 2:355–393.
   PubMed Web of Science ®Google Scholar
• Bertin GI, Sabbagh A, Argy N, Salnot V, Ezinmegnon S, Agbota G, Ladipo Y, Alao JM, Sagbo G, Guillonneau F, et al. 2016. Proteomic analysis of Plasmodium falciparum parasites from patients with cerebral and uncomplicated malaria. Sci Rep. 6:26773.
   PubMed Web of Science ®Google Scholar
• Booker ML, Bastos CM, Kramer ML, Barker RH, Jr., Skerlj R, Sidhu AB, Deng X, Celatka C, Cortese JF, Guerrero Bravo JE, et al. 2010. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J Biol Chem. 285:33054–33064.
   PubMed Web of Science ®Google Scholar
• Brau ME, Branitzki P, Olschewski A, Vogeland W, Hempelmann G. 2000. Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 91:1499–1505.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Sajiv N, Kang P, Loi CM. 2010. Metabolism pharmacokinetics and toxicity of functional groups. Chapter 6, Influence of aromatic rings on ADME properties of drugs. Cambridge: Royal Society of Chemistry. p. 275–327.
   Google Scholar
• Deepak DD, Sajiv N, Ping K, Cho-Ming L. 2010. Influence of aromatic rings on ADME properties of drugs. Metabolism, pharmacokinetics and toxicity of functional groups: impact of chemical building blocks on ADMET. R Soc Chem. 1:286–287.
   Google Scholar
• Deng L, Diao J, Chen P, Pujari V, Yao Y, Cheng G, Crick DC, Prasad BVV, Song Y. 2011. Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR and crystallographic studies. J Med Chem. 54:4721–4734.
   PubMed Web of Science ®Google Scholar
• Ghibellini GL, Leslie EM, Brouwer KL. 2006. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm. 3:198–211.
   PubMed Web of Science ®Google Scholar
• Gulluoglu MT, Erdogdu Y, Yurdakul S. 2007. Molecular structure and vibrational spectra of piperidine and 4-methylpiperidine by density functional theory and ab initio Hartree-Fock calculations. J Mol Struct. 834–836:540–547.
   Web of Science ®Google Scholar
• Haemers T, Wiesner J, Giessmann D, Verbrugghen T, Hillaert U, Ortmann R, Jomaa H, Link A, Schlitzer M, Van Calenbergh S. 2008. Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates. Bioorg Med Chem. 16:3361–3371.
   PubMed Web of Science ®Google Scholar
• Hassan SF, Rashid U, Ansari FL, Ul-Haq Z. 2013. Bioisosteric approach in designing new monastrol derivatives: an investigation on their ADMET prediction using in silico derived parameters. J Mol Graphics Modell. 45:202–210.
   Google Scholar
• Hitchcock SA. 2012. Structural modifications that alter the P-glycoprotein efflux properties of compounds. J Med Chem. 55:4877–4895.
   PubMed Web of Science ®Google Scholar
• Molinspiration: 2012. Available from: http://www.molinspiration.com/
   Google Scholar
• Hutcheson JD, Setola V, Roth BL, Merryman WD. 2011. Serotonin receptors and heart valve disease-It was meant 2B. Pharmacol Ther. 132:146–157.
   PubMed Web of Science ®Google Scholar
• Jansson AM, Więckowska A, Björkelid C, Yahiaoui S, Sooriyaarachchi S, Lindh M, Bergfors T, Dharavath S, Desroses M, Suresh S, et al. 2013. DXR inhibition by potent mono- and disubstituted fosmidomycin analogues. J Med Chem. 56:6190–6199.
   PubMed Web of Science ®Google Scholar
• Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. 2007. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 25:197–206.
   PubMed Web of Science ®Google Scholar
• Khalid H, Rehman AU, Abbasi MA, Khan KM, Ashraf M, Ahmad I, Ejaz SA. 2013. Synthesis of biologically active O-substituted derivatives of 1- [(3, 5-dichloro-2-hydroxyphenyl)sulfonyl]piperidine. Pak J Pharm Sci. 26:479–485.
   PubMed Web of Science ®Google Scholar
• Kuemmerle HP, Murakawa T, Soneoka K, Konishi T. 1985. Fosmidomycin: a new phosphonic acid antibiotic. Part I: phase I tolerance studies. Int J Clin Pharmacol Ther Toxicol. 23:515–520.
   PubMed Web of Science ®Google Scholar
• Kurz T, Behrendt C, Pein M, Kaula U, Bergmann B, Walter RD. 2007. Gamma-substituted bis(pivaloyloxymethyl)ester analogues of fosmidomycin and FR900098. Arch Pharm (Weinheim). 340:661–666.
   PubMed Web of Science ®Google Scholar
• LaBella FS. 1991. Molecular basis for binding promiscuity of antagonist drugs. Biochem Pharmacol. 42:S1–S8.
   PubMed Web of Science ®Google Scholar
• Labute P. 2008. The generalized born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem. 29:1693–1698.
   PubMed Web of Science ®Google Scholar
• Langer T, Hoffmann RD. 2006. Pharmacophores: historical perspective and viewpoint from a medicinal chemist. In: Wermuth CG, editor. Pharmacophores and pharmacophore searches. vol. 32. Germany: Wiley-VCH. pp. 3–13.
   Google Scholar
• Langer T. 2011. Pharmacophores in drug research. Mol Inf. 29:470–475.
   Web of Science ®Google Scholar
• Langer T. 2011. Pharmacophores for medicinal chemists: a personal view. Future Med Chem. 3:901–904.
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Giovanni DC. 2013. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem. 20:2839–2860.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv Drug Deliv Rev. 23:3–25.
   Web of Science ®Google Scholar
• Marvin 6.0.0, 2013. Available from: http://www.chemaxon.com
   Google Scholar
• Meyers RA. 2008. Pharmacology: from drug development to gene therapy. vol. 1. England: Wiley-Blackwell. pp. 1126.
   Google Scholar
• Molecular Operating Environment (MOE), Chemical Computing Group Inc., 2014-15. Montreal, QC, Canada.
   Google Scholar
• Muiegge I. 2003. Selection criteria for drug-like compounds. Med Res Rev. 2:302–321.
   Web of Science ®Google Scholar
• Murakawa T, Sakamoto H, Fukada S, Konishi T, Nishida M. 1982. Pharmacokinetics of Fosmidomycin, a new phosphonic acid antibiotic. Antimicrob Agents Chemother. 21:224–230.
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K, Ruengweerayut R, Karbwang J, Chauemung A, Hutchinson D. 2007. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar J. 6:70.
   PubMed Web of Science ®Google Scholar
• Ortmann R, Wiesner J, Silber K, Klebe G, Jomaa H, Schlitzer M. 2007. Novel deoxyxylulose phosphate reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues. Arch Pharm (Weinheim). 340:483–490.
   PubMed Web of Science ®Google Scholar
• Pacifici GM1, Nottoli R. 1995. Placental transfer of drugs administered to the mother. Clin Pharmacokinet. 28:235–269.
   PubMed Web of Science ®Google Scholar
• Pearlstein R, Vaz R, Rampe D. 2003. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem. 46:2017–2022.
   PubMed Web of Science ®Google Scholar
• Peters JU, Hert J, Bissantz C, Hillebrecht A, Gerebtzoff G, Bendels S, Tillier F, Migeon J, Fischer H, Guba W, et al. 2012. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Disc. 17:325–335.
   Google Scholar
• Phillips MA, Rathod PK. 2010. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 10:226–239.
   PubMedGoogle Scholar
• Priya K, Saravanan K, Selvanayagam S, Kabilan S. 2015. Crystal structure of 2-[4(E)-2,6-bis-(4-chloro-phen-yl)-3-ethyl-piperidin-4-yl-idene]acetamide. Acta Cryst. 71:o832–o833.
   Google Scholar
• Proteau PJ. 2004. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase: an overview. Bioorg Chem. 32:483–493.
   PubMed Web of Science ®Google Scholar
• Proudfoot JR. 2005. The evolution of synthetic oral drug properties. Bioorg Med Chem Lett. 15:1087–1090.
   PubMed Web of Science ®Google Scholar
• Queiroz RBD, Carvalho FLD, Fonsêca DVD, Barbosa-Filho JM, Salgado PRR, Paulo LL, Queiroz ABMD, Pordeus LCDM, Souza SAD, Souza HDDS. 2015. Antinociceptive effect of hydantoin 3-phenyl-5-(4-ethylphenyl)-imidazolidine-2,4-dione in mice. Molecules. 20:974–986.
   PubMed Web of Science ®Google Scholar
• Rashid U, Batool I, Wadood A, Khan A, ul-Haq Z, Chaudhary MI, Ansari FL. 2013. Structure based virtual screening-driven identification of monastrol as a potent urease inhibitor. J Mol Graph Model. 43:47–57.
   PubMed Web of Science ®Google Scholar
• Rehman W, Haq S, Muhammad B, Hassan SF, Badshah A, Waseem M, Rahim F, Ansari FL, Rashid U. 2014. Organotin (IV) based complexes as promiscuous antibacterials: synthesis, in vitro, in silico pharmacokinetic and docking studies. J Organometall Chem. 767:91–100.
   Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. 2000. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 102:2836–2841.
   PubMed Web of Science ®Google Scholar
• Singh N, Chevé G, Avery MA, McCurdy CR. 2007. Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme. Curr Pharm Des. 13:1161–1177.
   PubMed Web of Science ®Google Scholar
• Smith DA, Jones BC, Walker DK. 1996. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev. 16:243–266.
   PubMed Web of Science ®Google Scholar
• Tahar R, Basco LK. 2007. Molecular epidemiology of malaria in Cameroon. XXV. In vitro activity of fosmidomycin and its derivatives against fresh clinical isolates of Plasmodium falciparum and sequence analysis of 1-deoxy-D-xylulose 5-phosphate reductoisomerase. Am J Trop Med Hyg. 77:214–220.
   PubMed Web of Science ®Google Scholar
• Thangapandian S, John S, Sakkiah S, Lee KW. 2011. Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. Eur J Med Chem. 46:2469–2476.
   PubMed Web of Science ®Google Scholar
• Umeda T, Tanaka N, Kusakabe Y, Nakanishi M, Kitade Y Kazuo T., Nakamura 2011. Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparum. Nat Sci Rep. 1:9.
   PubMed Web of Science ®Google Scholar
• Vaichtanankul J, Taweechai S, Uttamapinant C, Chitnumsub P, Vilaivan T, Yuthavong Y, Kamchonwongpaisan S. 2012. Combined spatial limitation around residues 16 and 108 of Plasmodium falciparum dihydrofolate reductase explains resistance to cycloguanil. Antimicrob Agents Chemother. 56:3928–3935.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Gifford E. 2003. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2:192–204.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Smith DA, Jones BC. 2001. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Design. 15:273–286.
   PubMed Web of Science ®Google Scholar
• Wadood A, Ali SA, Sattar R, Lodhi MA, Ul-Haq Z. 2012. A novel pharmacophore model to identify leads for simultaneous inhibition of anti-coagulation and anti-inflammatory activities of snake venom phospholipase A2. Chem Biol Drug Des. 79:431–441.
   PubMed Web of Science ®Google Scholar
• Wadood A, Riaz M, Uddin R, Ul-Haq Z. 2014. In Silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. PLoS One. 9:e89109.
   PubMed Web of Science ®Google Scholar
• Wadood A, Ul-Haq Z. 2013. In silico identification of novel inhibitors against Plasmodium falciparum dihydroorate dehydrogenase. J Mol Graph Model. 40:40–47.
   PubMed Web of Science ®Google Scholar
• Watanuki S, Matsuura K, Tomura Y, Okada M, Okazaki T, Ohta M, Tsukamoto SI. 2011. Synthesis and pharmacological evaluation of 1-Alkyl-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents. Chem Pharm Bull. 59:1376–1385.
   PubMed Web of Science ®Google Scholar
• Wiesner J, Ortmann R, Jomaa H, Schlitzer M. 2007. Double ester prodrugs of FR900098 display enhanced in-vitro antimalarial activity. Arch Pharm (Weinheim). 340:667–669.
   PubMed Web of Science ®Google Scholar
• Winzeler EA. 2008. Malaria research in the post-genomic era. Nature. 455:751–756.
   PubMed Web of Science ®Google Scholar
• Simulations Plus, Inc. 2014. Available from: www.simulations-plus.com
   Google Scholar
• Xue J, Diao J, Cai G, Deng L, Zheng B, Yao Y, Song Y. 2013. Antimalarial and structural studies of pyridine-containing inhibitors of 1-deoxyxylulose-5-phosphate reductoisomerase. ACS Med Chem Lett. 4:278–282.
   PubMed Web of Science ®Google Scholar
• Yang Y, Engkvist O, Llinàs A, Chen H. 2012. Beyond size, ionization state and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for drug-like compounds. J Med Chem. 55:3667–3677.
   PubMed Web of Science ®Google Scholar
• Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y. 2003. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 10:357–365.
   PubMedGoogle Scholar
• Zhang Y, Huang C, Kim S, Golkaram M, Dixon MW, Tilley L, Li J, Zhang S, Suresh S. 2015. Multiple stiffening effects of nanoscale knobs on human red blood cells infected with Plasmodium falciparum malaria parasite. Proc Natl Acad Sci USA. 112:6068–6073.
   PubMed Web of Science ®Google Scholar